The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The SURVIVE study: Standard surveillance vs. intensified liquid biopsy-based surveillance in early breast cancer survivors.
 
Henning Schäffler
Honoraria - Daiichi Sankyo; Gilead Sciences; Novartis
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis
 
Sophia Huesmann
No Relationships to Disclose
 
Thomas Friedl
Honoraria - Lilly; Novartis
 
Kerstin Pfister
Honoraria - Gilead Sciences; Novartis; Pfizer
Research Funding - AstraZeneca (Inst)
 
Angelina Fink
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
 
Franziska Mergel
Travel, Accommodations, Expenses - Lilly
 
Tatjana Braun
No Relationships to Disclose
 
Forca Mehmeti
No Relationships to Disclose
 
Natalie Uhl
No Relationships to Disclose
 
Sabine Heublein
Consulting or Advisory Role - MSD; Novartis
Speakers' Bureau - Abbvie; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Pfizer; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Novartis
 
Andreas Hartkopf
Honoraria - Agendia; Amgen; AstraZeneca; Daiichi Sankyo; Genomic Health; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
 
Volkmar Mueller
Honoraria - Amgen; AstraZeneca; ClinSol; Daiichi Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Tesaro
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; Hexal; Lilly; Medac; MSD Oncology; Roche; Seagen
Research Funding - Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Pfizer; Roche
 
Lisa Wiesmueller
No Relationships to Disclose
 
Tanja Fehm
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; MSD Oncology; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Brigitte Rack
Honoraria - AstraZeneca; Daiichi Sankyo; Roche
Research Funding - Cellgen (Inst); Eisai (Inst); Guardant Health (Inst); Inivata (Inst); Lilly (Inst); Menarini (Inst); Roche (Inst)
 
Peter Fasching
Honoraria - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; SeaGen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Guardant Health; Hexal; Lilly; Menarini Group; Merck Sharp & Dohme; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Veracyte
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Pfizer (Inst); Roche
 
Wolfgang Janni
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Menarini Silicon Biosystems; Novartis; Pfizer; Roche; Seagen
Research Funding - Amgen (Inst); Janssen Diagnostics; Lilly (Inst); Menarini Silicon Biosystems; NeoGenomics Laboratories (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Lilly; Novartis; Pfizer; Roche